C Diff Treatment

Dr. Johnson ends his talk by sharing some ongoing research projects to mitigate and prevent C. difficile recurrences @esnm_eu #GMFHCoverage pic.twitter.com/9P5pHztWuL— GutMicrobiota Health (@GMFHx) October 12, 2022

Johnson: Lots of unanswered questions exist regarding the use of anti C. difficile infection antibiotics for prophylaxis. For instance, too high doses disrupt the microbiome boosting the risk of C. difficile infection @esnm_eu #GMFHCoverage pic.twitter.com/uO45G6rabk— GutMicrobiota Health (@GMFHx) October 12, 2022

When it comes to prevention strategies for C. difficile infection recurrence, Dr. Johnson acknowledges that probiotics, discontinuation of proton pump inhibitors and prophylactic-CDI options are not recommended @esnm_eu #GMFHCoverage pic.twitter.com/tbzMnFoB0e— GutMicrobiota Health (@GMFHx) October 12, 2022

Johnson: Fidaxomicin is recommended in various guidelines as an initial C. difficile infection treatment, while fecal transplants and standard of care plus Bexlotoxumab are not recommended in the initial episode @esnm_eu #GMFHCoverage pic.twitter.com/jsvghDkfk5— GutMicrobiota Health (@GMFHx) October 12, 2022

Recent interesting data presented now by Dr. Johnson suggest it is cost-effective adding Bexlotoxumab to CDI antibiotics alone for reducing recurrence @esnm_eu #GMFHCoverage pic.twitter.com/3UV6hy82Bw— GutMicrobiota Health (@GMFHx) October 12, 2022

Steven Johnson starts his talk highlighting the fact that recurrence is one of the major challenges to face: more than 60% to 65% recurrences after 3 or more C. difficile infection episodes @esnm_eu #GMFHCoverage pic.twitter.com/v8pZbNTfK0— GutMicrobiota Health (@GMFHx) October 12, 2022

Take-home messages from Prof. Iqbal on available management options for severe C. difficile infection @esnm_eu #GMFHCoverage pic.twitter.com/ZHowYyjwxf— GutMicrobiota Health (@GMFHx) October 12, 2022

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Our systematic review and meta-analysis found fidaxomicin was consistently associated with a lower risk of CDI recurrence than vancomycin. These results confirm CDI guideline recommendations and indicate that fidaxomicin may be preferred over vancomycin to minimize CDI recurrence across multiple cli …

Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective management is critical since the morbidity and mortality attributed to CDI have increased exponentially over …

Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective management is critical since the morbidity and mortality attributed to CDI have increased exponentially over …

Mitigating the risk for readmission and recurrence will enhance C. diff infection care, safety, and outcomes to improve a patient's health care journey and quality of life. Case managers need to take a primary role in the transition and care coordination processes, including patient and support syst …

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Mitigating the risk for readmission and recurrence will enhance C. diff infection care, safety, and outcomes to improve a patient's health care journey and quality of life. Case managers need to take a primary role in the transition and care coordination processes, including patient and support syst …

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

DEINOVE présente des données sur #DNV3837 au congrès ESCMID/ASM à Dublin. L'utilisation du DNV3837 est un changement de paradigme potentiel pour le traitement de l'infection par #CDiff permettant de traiter l’intestin dans son ensemble.https://t.co/QFH7TOZ2me pic.twitter.com/u2DQJEwc7E— Deinove (@Deinove) October 5, 2022

#Cdiff 2nd recurrence, after Po Vanco (initial), then Po fidaxomicin (1st recurrence). No bezlotoxumab. What to give on 2nd recurrence?— Ricardo Cedeno-Mendoza, MD (@ricardocedenomd) October 4, 2022

Ulcerative colitis is a chronic debilitating inflammatory bowel disease with no curative treatment currently available. INRAE scientists have developed a novel predictive model of disease progression in pediatric patients that integrates both gut microbiota and host inflammation data.

In terms of clinical cure rates and adverse event rates in Clostridioides difficile infection (CDI) patients, fidaxomicin (FDX) is equivalent to vancomycin (VCM) and yields noticeably greater...

Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These featu …

Researchers assessed whether fidaxomicin is superior to vancomycin in patients with C difficile infection.

Not sure what is the best advice you can offer to your patients in terms of fixing gut-related issues? This infographic summarizes what works based on sound science: pic.twitter.com/BghKOLgyfS— GutMicrobiota Health (@GMFHx) September 30, 2022

The closely related terms “fiber”, “microbiota-accessible carbohydrates” (or MACs) and “prebiotics” probably sound familiar. But what exactly are they and how can they contribute to promoting health and abrogating disease by shaping the gut microbiome? https://t.co/4onLUef1Ev— GutMicrobiota Health (@GMFHx) September 27, 2022

Initial vancomycin was associated with a reduced rate of new incident infection in the treatment of adult inpatients with first-episode non-severe CDI. These findings support the use of initial vancomycin for all inpatients with CDI, when fidaxomicin is unavailable.

Are you ready to attend the next @esnm_eu webinar on the management of recurrence of C. difficile infection?🗣 Daniel Pohl, Steven Johnson & Tariq Iqbal.👉 Join us on 12th October: https://t.co/GUYnBtIJOc pic.twitter.com/HdNsXTRYVw— GutMicrobiota Health (@GMFHx) September 28, 2022

Now at #LDDC22 at @ECCLeiden ; come to the sesssion on the Future of Anti-Infectives to hear my perspective on the future of #cdiff therapeutics @cdiffFoundation @Leidenbsp https://t.co/ViXCpEWS7k— Wiep Klaas Smits (@SmitsLab) September 27, 2022